Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy

Metabolism: Clinical and Experimental

Volumn 58, Issue 11, 2009, Pages 1523-1529

  Han, Sang Hoon ^a   Chin, Bum Sik ^a   Lee, Han Sung ^a   Jeong, Su Jin ^a   Choi, Hee Kyoung ^a   Kim, Chang Oh ^a   Choi, Jun Yong ^a   Song, Young Goo ^a   Lee, Hyun Chul ^a   Kim, June Myung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; RETINOL BINDING PROTEIN 4; TRIACYLGLYCEROL; LIPID; PLASMA RETINOL BINDING PROTEIN; RBP4 PROTEIN, HUMAN; VIRUS RNA;

ABDOMINAL FAT; ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMPEDANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; WAIST CIRCUMFERENCE; WAIST HIP RATIO; ABDOMEN; BLOOD; BLOOD PRESSURE; CROSS-SECTIONAL STUDY; DRUG EFFECT; ECHOGRAPHY; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ABDOMEN; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; BLOOD PRESSURE; BODY COMPOSITION; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; OBESITY; RETINOL-BINDING PROTEINS, PLASMA; RNA, VIRAL; WAIST CIRCUMFERENCE;

EID: 70449723309     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.04.021     Document Type: Article

References (40)

1. Michaels S.H., Clark R., and Kissinger P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 339 (1998) 405-406
2. Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Ther 13 (2006) 248-260
3. Estrada V., Martinez-Larrad M.T., Gonzalez-Sanchez J.L., et al. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism 55 (2006) 940-945
4. Grinspoon S., and Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352 (2005) 48-62
5. Bulcao C., Ferreira S.R., Giuffrida F.M., et al. The new adipose tissue and adipocytokines. Curr Diabetes Rev 2 (2006) 19-28
6. Addy C.L., Gavrila A., Tsiodras S., et al. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 88 (2003) 627-636
7. Oral E.A., Simha V., Ruiz E., et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 346 (2002) 570-578
8. Barb D., Wadhwa S.G., Kratzsch J., et al. Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome. J Clin Endocrinol Metab 90 (2005) 5324-5328
9. Quadro L., Blaner W.S., Salchow D.J., et al. Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein. Embo J 18 (1999) 4633-4644
10. Cho Y.M., Youn B.S., Lee H., et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 29 (2006) 2457-2461
11. Graham T.E., Yang Q., Bluher M., et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354 (2006) 2552-2563
12. von Eynatten M., Lepper P.M., Liu D., et al. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia 50 (2007) 1930-1937
13. Lee J.W., Im J.A., Lee H.R., et al. Visceral adiposity is associated with serum retinol binding protein-4 levels in healthy women. Obesity (Silver Spring) 15 (2007) 2225-2232
14. Perseghin G., Lattuada G., De Cobelli F., et al. Serum retinol-binding protein-4, leptin, and adiponectin concentrations are related to ectopic fat accumulation. J Clin Endocrinol Metab 92 (2007) 4883-4888
15. Qi Q., Yu Z., Ye X., et al. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in chinese people. J Clin Endocrinol Metab 92 (2007) 4827-4834
16. Schindler K., Haider D., Wolzt M., et al. Impact of antiretroviral therapy on visfatin and retinol-binding protein 4 in HIV-infected subjects. Eur J Clin Invest 36 (2006) 640-646
17. World Health Organization. International statistical classification of diseases and related health problems. 10th revision, 2nd ed (2006), World Health Organization, Geneva
18. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
19. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
20. Katz A., Nambi S.S., Mather K., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000) 2402-2410
21. Demura S., Sato S., and Kitabayashi T. Percentage of total body fat as estimated by three automatic bioelectrical impedance analyzers. J Physiol Anthropol Appl Human Sci 23 (2004) 93-99
22. Choi J.W., and Pai S.H. Bone mineral density correlates strongly with basal metabolic rate in postmenopausal women. Clin Chim Acta 333 (2003) 79-84
23. US National Institutes of Health DAIDS HIV Vaccines and Research Program. National Institutes of Health. Division of AIDS (DAIDS) revised toxicity tables for grading the severity of adult and pediatric adverse events experiences, version 1.0, December 2004, Washington. DC. Available at. http://rcc.tech-res.com/tox_tables.htm
24. Suzuki R., Watanabe S., Hirai Y., et al. Abdominal wall fat index, estimated by ultrasonography, for assessment of the ratio of visceral fat to subcutaneous fat in the abdomen. Am J Med 95 (1993) 309-314
25. Ribeiro-Filho F.F., Faria A.N., Kohlmann Jr. O., et al. Ultrasonography for the evaluation of visceral fat and cardiovascular risk. Hypertension 38 (2001) 713-717
26. Armellini F., Zamboni M., Robbi R., et al. Total and intra-abdominal fat measurements by ultrasound and computerized tomography. Int J Obes Relat Metab Disord 17 (1993) 209-214
27. Pignoli P., Tremoli E., Poli A., et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74 (1986) 1399-1406
28. Yanase T., Nasu S., Mukuta Y., et al. Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, Intimascope. Am J Hypertens 19 (2006) 1206-1212
29. Gavi S., Qurashi S., Stuart L.M., et al. Influence of age on the association of retinol-binding protein 4 with metabolic syndrome. Obesity (Silver Spring) 16 (2008) 893-895
30. Rexrode K.M., Buring J.E., and Manson J.E. Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord 25 (2001) 1047-1056
31. Haider D.G., Schindler K., Mittermayer F., et al. Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients. Clin Pharmacol Ther 81 (2007) 580-585
32. Kloting N., Graham T.E., Berndt J., et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab 6 (2007) 79-87
33. Hertel J., Struthers H., Horj C.B., et al. A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem 279 (2004) 55147-55152
34. Young J., Weber R., Rickenbach M., et al. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 10 (2005) 585-591
35. Wierzbicki A.S., Purdon S.D., Hardman T.C., et al. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Curr Med Res Opin 24 (2008) 609-624
36. Chen D., Misra A., and Garg A. Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 87 (2002) 4845-4856
37. Kim R.J., Wilson C.G., Wabitsch M., et al. HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity (Silver Spring) 14 (2006) 994-1002
38. Toma E., Devost D., Chow Lan N., et al. HIV-protease inhibitors alter retinoic acid synthesis. Aids 15 (2001) 1979-1984
39. Thomson R., Brinkworth G.D., Buckley J.D., et al. Good agreement between bioelectrical impedance and dual-energy x-ray absorptiometry for estimating changes in body composition during weight loss in overweight young women. Clin Nutr 26 (2007) 771-777
40. Nagai M., Komiya H., Mori Y., et al. Development of a new method for estimating visceral fat area with multi-frequency bioelectrical impedance. Tohoku J Exp Med 214 (2008) 105-112